Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 1/20 | 0.39 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.39 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | AHCY | P23526 | 1/20 | 0.38 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.37 |
| ▸ | ADCY5 | O95622 | 4/20 | 0.37 |
| ▸ | GNMT | Q14749 | 1/20 | 0.37 |
| ▸ | MARS1 | P56192 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL718524 | 0.86 | POLB (0.45) | P2RX3P2RX4P2RX2ADORA1POLB | |
| SCHEMBL2835834 | 0.86 | POLB (0.45) | P2RX3P2RX4P2RX2ADORA1POLB | |
| SCHEMBL718788 | 0.81 | POLB (0.37) | POLB | |
| SCHEMBL888256 | 0.77 | STING1 (0.42) | POLBAHCYSTING1 | |
| SCHEMBL30206539 | 0.76 | POLB (0.44) | ADORA1POLBAHCYSTING1MARS1 | |
| SCHEMBL1140624 | 0.74 | ADORA1 (0.41) | ADORA1AHCYSTING1 | |
| SCHEMBL717274 | 0.74 | KDM4E (0.41) | POLBSTING1 | |
| SCHEMBL1901202 | 0.73 | POLB (0.42) | P2RX3P2RX4P2RX2ADORA1POLB | |
| SCHEMBL29720490 | 0.73 | TYMP (0.51) | ADORA1POLB | |
| SCHEMBL18844344 | 0.72 | P2RY12 (0.41) | ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11940413-B2 | Methods and devices for sequencing nucleic acids in smaller batches | IsoPlexis Corporation (US) | 2024-03-26 | — | — | US | disclosed |
| US-20240076731-A1 | METHODS AND COMPOSITIONS FOR INCORPORATING NUCLEOTIDES | QIAGEN SCIENCES, LLC | 2024-03-07 | — | — | US | disclosed |
| US-20240060128-A1 | METHODS AND COMPOSITIONS FOR INCORPORATING NUCLEOTIDES | QIAGEN WALTHAM, INC. | 2024-02-22 | — | — | US | disclosed |
| US-20230407384-A1 | METHODS AND COMPOSITIONS FOR INCORPORATING NUCLEOTIDES | QIAGEN WALTHAM, INC. | 2023-12-21 | — | — | US | disclosed |
| US-11390858-B2 | Modified template-independent enzymes for polydeoxynucleotide synthesis | Molecular Assemblies, Inc. (US) | 2022-07-19 | — | — | US | disclosed |
| US-20210231609-A1 | METHODS AND DEVICES FOR SEQUENCING NUCLEIC ACIDS IN SMALLER BATCHES | IsoPlexis Corporation | 2021-07-29 | — | — | US | disclosed |
| US-20210230686-A1 | METHODS AND COMPOSITIONS FOR INCORPORATING NUCLEOTIDES | IsoPlexis Corporation | 2021-07-29 | — | — | US | disclosed |
| US-11035823-B2 | Methods and devices for sequencing nucleic acids in smaller batches | QIAGEN SCIENCES, LLC (US) | 2021-06-15 | — | — | US | disclosed |
| US-11001887-B2 | Methods and compositions for incorporating nucleotides | QIAGEN SCIENCES, LLC (US) | 2021-05-11 | — | — | US | disclosed |
| US-20210009969-A1 | MODIFIED TEMPLATE-INDEPENDENT ENZYMES FOR POLYDEOXYNUCLEOTIDE SYNTHESIS | Molecular Assemblies, Inc. | 2021-01-14 | — | — | US | disclosed |
| US-20130301888-A1 | Methods And Compositions For Base Calling Nucleic Acids | IsoPlexis Corporation | 2013-11-14 | — | — | US | disclosed |
| US-8481259-B2 | Methods and devices for sequencing nucleic acids in smaller batches | INTELLIGENT BIO-SYSTEMS, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-20130137091-A1 | Methods And Compositions For Incorporating Nucleotides | INTELLIGENT BIO-SYSTEMS, INC. | 2013-05-30 | — | — | US | disclosed |
| US-20120052489-A1 | METHODS AND COMPOSITIONS FOR SEQUENCING NUCLEIC ACIDS USING CHARGE | INTELLIGENT BIO-SYSTEMS, INC. | 2012-03-01 | — | — | US | disclosed |
| US-20110124054-A1 | Methods And Compositions For Inhibiting Undesired Cleaving Of Labels | INTELLIGENT BIO-SYSTEMS, INC. | 2011-05-26 | — | — | US | disclosed |
| US-20100330569-A1 | Hydroxymethyl Linkers For Labeling Nucleotides | INTELLIGENT BIO-SYSTEMS, INC. | 2010-12-30 | — | — | US | disclosed |
| US-20100323350-A1 | Methods And Devices For Sequencing Nucleic Acids In Smaller Batches | INTELLIGENT BIOSYSTEMS, INC. | 2010-12-23 | — | — | US | disclosed |
| US-20100159531-A1 | Methods And Solutions For Inhibiting Undesired Cleaving Of Labels | INTELLIGENT BIO-SYSTEMS, INC. | 2010-06-24 | — | — | US | disclosed |
| US-20100063743-A1 | Methods And Compositions For Base Calling Nucleic Acids | INTELLIGENT BIO-SYSTEMS, INC. | 2010-03-11 | — | — | US | disclosed |
| US-20100035253-A1 | Methods And Compositions For Incorporating Nucleotides | INTELLIGENT BIO-SYSTEMS, INC. | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210230686-A1 | METHODS AND COMPOSITIONS FOR INCORPORATING NUCLEOTIDES | NT5C2, NOP2, NT5C3B | P2RX3 216/4885P2RX4 395/4885P2RX2 305/4885 |
| US-20240076731-A1 | METHODS AND COMPOSITIONS FOR INCORPORATING NUCLEOTIDES | NT5C2, NOP2, NT5C3B | P2RX3 216/4885P2RX4 395/4885P2RX2 305/4885 |
| US-11001887-B2 | Methods and compositions for incorporating nucleotides | NT5C2, NOP2, NT5C3B | P2RX3 216/4885P2RX4 395/4885P2RX2 305/4885 |
| US-20230407384-A1 | METHODS AND COMPOSITIONS FOR INCORPORATING NUCLEOTIDES | NT5C2, NOP2, NT5C3B | P2RX3 216/4885P2RX4 395/4885P2RX2 305/4885 |
| US-20240060128-A1 | METHODS AND COMPOSITIONS FOR INCORPORATING NUCLEOTIDES | NT5C2, NOP2, NT5C3B | P2RX3 216/4885P2RX4 395/4885P2RX2 305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.